Jamie Holz
Psychiatric/Mental Health · Oklahoma City, OKNPI 1912565995
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Alkermes, Inc. at 24.2% of the total. Reporting peaked in 2022 at $2,145 and has fallen 76.9% since, to $495 in 2025.
Across 314 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$547
- Neurocrine Biosciences, Inc.$466
- E.r. Squibb & Sons, L.L.C.$448
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$414
- plus $2K from 8 others
What the payments were for
- Food & beverage$6,372100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 49 | $1,540 |
| Johnson & Johnson | 62 | $1,013 |
| Otsuka America Pharmaceutical, Inc. | 38 | $547 |
| Neurocrine Biosciences, Inc. | 15 | $466 |
| E.r. Squibb & Sons, L.L.C. | 13 | $448 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $414 |
| AbbVie | 34 | $411 |
| Teva Pharmaceuticals USA, Inc. | 21 | $393 |
| Lundbeck LLC | 19 | $371 |
| Indivior Inc. | 14 | $259 |
| Sunovion Pharmaceuticals Inc. | 13 | $258 |
| Vanda Pharmaceuticals Inc. | 11 | $203 |
| Supernus Pharmaceuticals, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,388
- ARISTADA$959
- INVEGA SUSTENNA$261
- COBENFY$244
- ARISTADA INITIO$240
- INGREZZA$235
- AUSTEDO$117
- OPDIVO$114
How this compares
$6,372 in reported general payments places this provider in the 85th percentile of 231 psychiatric/mental health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 15 | $117,440 |
| Austedo XrDeutetrabenazine | 13 | $75,824 |
| Abilify MaintenaAripiprazole | 19 | $52,757 |
| AristadaAripiprazole Lauroxil | 13 | $40,098 |
| Invega SustennaPaliperidone Palmitate | 12 | $32,299 |
| VraylarCariprazine Hcl | 15 | $21,480 |
| Aripiprazole | 71 | $4,162 |
| Paliperidone ErPaliperidone | 18 | $3,801 |
| Duloxetine Hcl | 64 | $1,873 |
| Hydroxyzine Pamoate | 61 | $1,847 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 26 | $1,754 |
| Bupropion XlBupropion Hcl | 58 | $1,440 |
| Quetiapine Fumarate | 53 | $1,385 |
| Hydroxyzine Hcl | 22 | $1,307 |
| Buspirone Hcl | 46 | $1,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $1,013 | $149,73927 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $393 | $75,82413 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $547 | $52,75719 claims |
| Alkermes, Inc.Aristada | $1,540 | $40,09813 claims |
| AbbVieVraylar | $411 | $21,48015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 231 psychiatric/mental health providers in Oklahoma.
Other psychiatric/mental health in Oklahoma City
- Sylvie MawohOklahoma City$14K
- Imelda GarnerOklahoma City$9K
- Kathryn SheltonOklahoma City$8K
- Nicole BrownOklahoma City$8K
- Ragina HolimanOklahoma City$7K
- Tierra PageOklahoma City$7K
- Kelsey WilsonOklahoma City$6K
- Robin Potter-KimballOklahoma City$6K
- Sue RollinsOklahoma City$6K
- Elizabeth MuburiOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.